Fairmount’s March 31 Surge: Converting Preferred to Common Signals Big Bet on Cogent’s Near‑Term Upside

Fairmount Funds’ March 31 Surge: A Signal or a Stop‑gap? On March 31, 2026, Fairmount Funds Management LLC executed a three‑part transaction that moved the equity balance sheet of Cogent Biosciences in a single day. First, 28,000 Series A Convertible Preferred shares were converted into 7 million common shares at no cash consideration, immediately increasing the company’s outstanding common shares by 7 million. Next, Fairmount bought 7 million shares at the closing price of $38.49, bringing its post‑transaction ownership to 12.5 million shares (≈ 21% of the public float). Finally, the firm sold 28,000 preferred shares, leaving its holdings of the preferred class unchanged at 39,414 shares.

This cascade is not just a routine liquidity move—it signals a shift in Fairmount’s stance on Cogent’s long‑term prospects. By converting preferred stock en masse, Fairmount demonstrates confidence in the company’s common‑stock value and a willingness to absorb potential dilution from future preferred issuances. The immediate buyback further suggests that Fairmount is betting on a near‑term upside, perhaps tied to the company’s latest clinical data releases or partnership announcements that have been quietly circulating in biotech circles.

Investor Implications Amidst a Volatile Biotech Landscape Cogent has been a high‑volatility play, with a market cap of roughly $5.86 billion and a P/E of –14.17, underscoring its unprofitable but high‑growth status. The recent 8.7% weekly gain, against a backdrop of a 572.9% year‑to‑date rally, indicates that the market is still rallying on the expectation of breakthrough therapies. Fairmount’s sizable stake now sits just below the 10% threshold that would trigger additional disclosure under SEC rules, meaning that the firm can maneuver relatively freely without attracting regulatory scrutiny.

From an investor standpoint, Fairmount’s move could be interpreted as a “buy the dip” tactic—capitalizing on the temporary price decline that follows conversion announcements, which often create a short‑term supply spike. If Cogent’s clinical pipeline advances, the company may issue additional preferred shares, and Fairmount’s earlier conversion positions it to benefit from the upside without further dilution. Conversely, if the company’s growth trajectory stalls, the influx of shares could exacerbate volatility, potentially draining value for smaller shareholders.

Fairmount Funds: A History of Tactical Preferred Play Fairmount’s past filing on January 22, 2026, shows a sell of 3.5 million common shares at $36.40, followed by a holding of 67,414 preferred shares. The firm’s pattern—selling common shares while maintaining a significant preferred balance—suggests a preference for the safety and fixed income of preferred securities, then converting when valuation conditions look attractive. The March conversions fit this mold: a strategic shift from holding preferred to owning common shares when the company’s price trajectory looks favorable.

Historically, Fairmount’s trades have been large‑scale and often correlated with the company’s broader insider activity, which includes significant sells by senior executives in December 2025. The pattern points to Fairmount as a tactical player: it monitors insider sentiment, capitalizes on conversion opportunities, and positions itself to ride potential upside while limiting downside exposure through its preferred holdings.

What This Means for Cogent’s Future With Fairmount now holding a sizable stake in common shares, the company gains a committed, long‑term investor that is willing to absorb dilution from future equity issuances. This can provide a cushion for future financing rounds, reducing the need for high‑yield debt or expensive public offerings. Moreover, Fairmount’s presence may signal confidence to other institutional investors, potentially smoothing the path for future capital raises and partnership deals.

On the flip side, the conversion and subsequent buyback increase the share count and could dilute earnings per share in the future, which may dampen short‑term price performance if investors react negatively to a perceived dilution. If Cogent’s clinical programs continue to progress, however, the additional equity supply could be offset by rising valuations, making Fairmount’s move a catalyst for further price appreciation.

Bottom Line for Investors Fairmount’s March 31 transaction is a calculated bet on Cogent’s near‑term upside and a strategic conversion of preferred to common equity. For shareholders, the move underscores a bullish outlook that could translate into higher valuations if the company’s pipeline succeeds. However, the increased share supply warrants attention, especially if future capital raises dilute earnings. Keeping an eye on subsequent quarterly earnings and clinical milestones will be essential to gauge whether Fairmount’s confidence is justified and how it will impact Cogent’s long‑term trajectory.